Efficacy and safety of meropenem and imipenem cilastatin in elderly pulmonary infection
10.3969/j.issn.1005-1678.2017.02.085
- VernacularTitle:美罗培南与亚胺培南西司他丁治疗老年肺部感染患者的疗效与安全性
- Author:
Xiufeng ZHANG
;
Xiaofang WANG
- Keywords:
pulmonary infection;
elderly patients;
meropenem;
imipenem cilastatin;
clinical efficacy;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(2):273-275
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study and compare the efficacy and safety of meropenem and imipenem cilastatin in the treatment of elderly patients with pulmonary infection.Methods A total of 124 elderly patients with pulmonary infection treated in our hospital were chosen.They were randomly divided into two groups.61 patients in the control group were treated with imipenem cilastatin, and 63 patients in the study group were treated with meropenem injection.After two weeks of treatment, the clearance rate of the pathogens, the effective rate of treatment and the incidence of adverse reactions were compared between the two groups.Results The clearance rate of pathogens in the study group was 98.41%, significantly higher than the control group (88.52%).There was no significant difference in effective rate between the study group (98.41%) and the control group(93.44%).There was no significant difference in incidence of adverse reactions between the study group (7.94%) and the control group (13.11%).Conclusion Meropenem or imipenem cilastatin has similar effective rate and adverse reactions , while meropenem could effectively eradicate bacterial infection in the treatment of pulmonary infection in elderly patients.
